Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

被引：0
|
作者：
Fatima Cardoso [1 ]
Kim M. Hirshfield [2 ]
Kimberly A. Kraynyak [2 ]
Konstantinos Tryfonidis [2 ]
Aditya Bardia [3 ]
机构：
[1] Champalimaud Clinical Center/Champalimaud Foundation,Breast Unit
[2] Inc.,Merck & Co.
[3] Jonsson Comprehensive Cancer Center,Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles
来源：
npj Breast Cancer | / 10卷 / 1期
关键词：
D O I：
10.1038/s41523-024-00704-9
中图分类号：
学科分类号：
摘要：
Additional therapies are needed to improve outcomes in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative breast cancer. Research on the potential role of immunotherapy, particularly programmed cell death protein 1/programmed cell death ligand 1 inhibitors, is rapidly expanding in both the early and metastatic settings with some preliminary evidence suggesting benefit when used as part of combination therapy. Several ongoing phase 3 studies should help define their future role in treating these patients.
引用
收藏
相关论文
共 50 条
  • [21] New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer
    Martinello, Rossella
    Genta, Sofia
    Galizia, Danilo
    Geuna, Elena
    Milani, Andrea
    Zucchini, Giorgia
    Valabrega, Giorgio
    Montemurro, Filippo
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (16) : 2179 - 2189
  • [22] Optimizing care for younger women with hormone receptor-positive, HER2-negative metastatic breast cancer
    de Boer, Richard
    Hui, Rina
    Lim, Elgene
    Yeo, Belinda
    Zdenkowski, Nicholas
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 3 - 14
  • [23] Characterization of Weakly Hormone Receptor (HR)-Positive, HER2-Negative Breast Cancer and Current Treatment Strategies
    Poterala, Johanna E.
    Havighurst, Thomas
    Wisinski, Kari Braun
    CLINICAL BREAST CANCER, 2022, 22 (06) : 611 - 618
  • [24] Current Management and Future Perspectives of Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
    Gilchrist, Jenny
    SEMINARS IN ONCOLOGY NURSING, 2024, 40 (01)
  • [25] Treatment differences by race and age in metastatic hormone receptor-positive/HER2-negative breast cancer
    Abdou, Yara
    Ivory, Joannie
    Deal, Allison
    Wardell, Ally
    Wheless, Amy
    Dees, Claire
    Carey, Lisa
    CANCER RESEARCH, 2024, 84 (09)
  • [26] Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases
    Minetta C. Liu
    Javier Cortés
    Joyce O’Shaughnessy
    Cancer and Metastasis Reviews, 2016, 35 : 323 - 332
  • [27] Patterns of chemotherapy receipt among patients with hormone receptor-positive, HER2-negative breast cancer
    Linnea T. Olsson
    Alina M. Hamilton
    Sarah C. Van Alsten
    Jennifer L. Lund
    Til Stürmer
    Hazel B. Nichols
    Katherine E. Reeder-Hayes
    Melissa A. Troester
    Breast Cancer Research and Treatment, 2024, 204 : 107 - 116
  • [28] Patterns of chemotherapy receipt among patients with hormone receptor-positive, HER2-negative breast cancer
    Olsson, Linnea T.
    Hamilton, Alina M.
    Van Alsten, Sarah C.
    Lund, Jennifer L.
    Sturmer, Til
    Nichols, Hazel B.
    Reeder-Hayes, Katherine E.
    Troester, Melissa A.
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 204 (01) : 107 - 116
  • [29] Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases
    Liu, Minetta C.
    Cortes, Javier
    O'Shaughnessy, Joyce
    CANCER AND METASTASIS REVIEWS, 2016, 35 (02) : 323 - 332
  • [30] PROGNOSTIC SIGNIFICANCE OF PgR EXPRESSION IN HORMONE-RECEPTOR POSITIVE, HER2-NEGATIVE, NODE-NEGATIVE BREAST CANCER
    Ono, Makiko
    Hitoshi, Tsuda
    Yoshida, Masayuki
    Shimizu, Chikako
    Kinoshita, Takayuki
    Tamura, Kenji
    ANNALS OF ONCOLOGY, 2014, 25
12345